Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF V600
BRAF V600 - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- In this Phase III trial (NCT01584648 COMBI-d), 423 previously untreated patients with unrescectable stage IIIC or IV BRAF V600E or V600K melanoma received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival with secondary endpoints including disease response. Hazard ratio for progression or death in the dabrafenib–trametinib group, 0.75; (95% confidence interval, 0.57 to 0.99; P=0.03). Of 210 patients in the dabrafenib + trametinib group, 67% of patients had a response, which was 16 percentage points higher than in the dabrafenib group. (95% CI, 6 to 25; P=0.002)
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6937
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/17
- Rating
- 5
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- Trametinib,Dabrafenib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25265492
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dabrafenib | Sensitivity | true |
| Trametinib | Sensitivity | true |